



PATENT
Atty. Docket No. PP016466.0002

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first-class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

July 2, 2009

By: Joy M. Marshelly

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Pablo Garcia, et al.
U.S. Application No. 10/016,604
Date Filed: December 7, 2001
Group Art Unit: 1648
Examiner: L. Humphrey
For: ENDOGENOUS RETROVIRUSES UP-REGULATED IN PROSTATE CANCER

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.56 AND §1.97(c)(2)

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

The citations listed on the enclosed Information Disclosure Form (Form PTO/SB/08A and PTO/SB/08B) may be material to the examination of the above-identified patent application. Therefore, Applicant submits these documents in compliance with the duty of disclosure as defined in 37 C.F.R. §1.56 and §1.97(c)(2). The Examiner is requested to make these citations of official record in the present application.

The present Information Disclosure Statement is being filed after the mailing date of the first Office action on the merits, and,

therefore, a \$180.00 fee under 37 C.F.R. §1.17(p) is required.

Some references enclosed are cited or submitted in US Patent Application No. 10/497,786, its PCT filed 12/09/2002, the European or the Japanese counterpart application of 10/497,786. 10/497,786 claims priority to the instant application. Some references enclosed are cited in the Japanese counterpart application of 10/497,786, Application No. 2003-551280. The relevance of Hatanaka et al., which is in Japanese, is shown on page 2 of the translated JPO office action mailed 8/19/08, submitted herein. A copy of the Supplemental European Search Report for EP Application No. 02786981.7 mailed on February 20, 2007 is submitted herein. An office action in 10/497,786 has also been submitted herein.

Some references enclosed are cited or submitted in US Patent Application No. 10/498,033, its PCT filed 12/09/2002, the European or the Japanese counterpart application of 10/498,033. 10/498,033 claims priority to the instant application. The relevance of Artamonova et al., which is in Russian, is shown as "technological background" in the March 13, 2007 Supplemental European Search Report for EP Application No. 02807929.1 which was mailed on June 22, 2007 and is submitted herein. An office action in 10/498,033 has also been submitted herein.

Some references enclosed are cited in the Response under 37


C.F.R. §1.111, submitted herein.

Copies of all the references that are not US patent documents are enclosed herein.

This Information Disclosure Statement under 37 C.F.R. §1.56 and §1.97(b)(3) is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that these citations constitute prior art under 35 U.S.C. §102 or §103.

Respectfully submitted,

By:



Mei Hong
Agent for Applicants
Reg. No. 55,276

Date: July 2, 2009

NOVARTIS VACCINES AND DIAGNOSTICS, INC.
Corporate Intellectual Property Dept.
4560 Horton Street
Emeryville, CA 94608-2916
Telephone: (510) 923-5413
Facsimile: (510) 655-3542